Sean Bohen, MD, PhD, Olema Oncology, San Francisco, CA, provides an overview of OP-1250, a complete estrogen receptor antagonist (CERAN). When it binds to the estrogen receptor (ER), it completely turns off the cell growth and proliferation signal mediated by the ER in ER-positive breast cancer cells. It additionally acts as a potent selective estrogen receptor degrader (SERD). OP-1250 is currently being developed as both a single agent and in combination with CDK4/6 inhibitors and a PI3K-alpha inhibitor. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.